A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19

J Virol Methods. 2021 Jan:287:114009. doi: 10.1016/j.jviromet.2020.114009. Epub 2020 Nov 2.

Abstract

Background: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection.

Objective: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection.

Results: Clinical agreement studies were performed in 107 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15 % (95 % CI: 19.22 % ∼74.87 %), 61.54 % (95 % CI: 31.58 % ∼86.14 %), and 97.53 % (95 % CI: 91.36 % ∼99.70 %) for samples collected on 0-7 days, 8-14 days, and ≥15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23 % (95 % CI: 95.53 % ∼99.52 %). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay.

Conclusion: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up anti-SARS-CoV-2 IgG testing.

Keywords: COVID-19; IgG test; Immunoassay; SARS-CoV-2.

Publication types

  • Evaluation Study

MeSH terms

  • Antibodies, Viral / blood
  • COVID-19 / blood
  • COVID-19 / diagnosis*
  • COVID-19 Serological Testing / methods*
  • High-Throughput Screening Assays
  • Humans
  • Immunoassay
  • Immunoglobulin G / blood*
  • Reproducibility of Results
  • SARS-CoV-2 / immunology*
  • SARS-CoV-2 / isolation & purification
  • Sensitivity and Specificity

Substances

  • Antibodies, Viral
  • Immunoglobulin G